INTRODUCTION: Surgery is the mainstay of staging and treatment of ovarian cancer. Optimal quality of ovarian cancer surgery implies complete staging and removal of all macroscopic tumour with minimal harm to the patient in order to ensure best patient outcome. However, variation in the quality of ovarian cancer surgery is apparent. In order to assess and improve the quality of care, quality indicators can be used. METHODS: To identify candidate quality indicators, a literature search was performed using relevant MESH terms. These were assessed for validity, feasibility and measurability. RESULTS: Five quality indicators for staging of presumed early-stage ovarian cancer and six for primary debulking surgery for advanced disease are proposed. CONCLUSION: The defined quality indicators can be used to monitor and improve the quality of surgery for ovarian cancer.
INTRODUCTION: Surgery is the mainstay of staging and treatment of ovarian cancer. Optimal quality of ovarian cancer surgery implies complete staging and removal of all macroscopic tumour with minimal harm to the patient in order to ensure best patient outcome. However, variation in the quality of ovarian cancer surgery is apparent. In order to assess and improve the quality of care, quality indicators can be used. METHODS: To identify candidate quality indicators, a literature search was performed using relevant MESH terms. These were assessed for validity, feasibility and measurability. RESULTS: Five quality indicators for staging of presumed early-stage ovarian cancer and six for primary debulking surgery for advanced disease are proposed. CONCLUSION: The defined quality indicators can be used to monitor and improve the quality of surgery for ovarian cancer.
Authors: Vincenzo Dario Mandato; Martino Abrate; Pierandrea De Iaco; Debora Pirillo; Gino Ciarlini; Maurizio Leoni; Giuseppe Comerci; Alessandro Ventura; Bruno Lenzi; Andrea Amadori; Federica Rosati; Ruby Martinello; Rossana De Palma; Chiara Ventura; Laura Maria Beatrice Belotti; Debora Formisano; Giovanni Battista La Sala Journal: J Ovarian Res Date: 2013-03-31 Impact factor: 4.234
Authors: Pawel Derlatka; Jacek Sienko; Laretta Grabowska-Derlatka; Piotr Palczewski; Anna Danska-Bidzinska; Mariusz Bidzinski; Krzysztof Czajkowski Journal: World J Surg Oncol Date: 2016-02-29 Impact factor: 2.754
Authors: Annemie Luyckx; Leen Wyckmans; Anne-Sophie Bonte; Xuan Bich Trinh; Peter A van Dam Journal: BMC Womens Health Date: 2020-07-23 Impact factor: 2.809
Authors: Laretta Grabowska-Derlatka; Pawel Derlatka; Wojciech Szeszkowski; Andrzej Cieszanowski Journal: Biomed Res Int Date: 2016-02-28 Impact factor: 3.411